NASDAQ:BDTX Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis $2.40 +0.12 (+5.26%) Closing price 04:00 PM EasternExtended Trading$2.42 +0.02 (+0.67%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Black Diamond Therapeutics Stock (NASDAQ:BDTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BDTX alerts:Sign Up Key Stats Today's Range$2.25▼$2.4350-Day Range$2.27▼$3.2152-Week Range$1.20▼$6.75Volume745,708 shsAverage Volume966,504 shsMarket Capitalization$136.46 millionP/E Ratio10.44Dividend YieldN/APrice Target$12.80Consensus RatingBuy Company Overview Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Read More Black Diamond Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreBDTX MarketRank™: Black Diamond Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 496th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBlack Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBlack Diamond Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Black Diamond Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Black Diamond Therapeutics are expected to grow in the coming year, from ($1.30) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Black Diamond Therapeutics is 40.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Black Diamond Therapeutics is 40.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.11.Price to Book Value per Share RatioBlack Diamond Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.66% of the outstanding shares of Black Diamond Therapeutics have been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 4.30%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlack Diamond Therapeutics does not currently pay a dividend.Dividend GrowthBlack Diamond Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.66% of the outstanding shares of Black Diamond Therapeutics have been sold short.Short Interest Ratio / Days to CoverBlack Diamond Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Black Diamond Therapeutics has recently increased by 4.30%, indicating that investor sentiment is decreasing. News and Social Media4.1 / 5News Sentiment1.34 News SentimentBlack Diamond Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Black Diamond Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for BDTX on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows7 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.97% of the stock of Black Diamond Therapeutics is held by insiders.Percentage Held by Institutions95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Black Diamond Therapeutics' insider trading history. Receive BDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BDTX Stock News HeadlinesBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives $12.80 Consensus PT from BrokeragesAugust 8 at 2:01 AM | americanbankingnews.comBlack Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7 at 7:30 AM | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 8 at 2:00 AM | Brownstone Research (Ad)Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows PromiseJuly 15, 2025 | msn.comBlack Diamond Therapeutics Inc. BDTX (U.S.: Nasdaq) - The Wall Street JournalJune 25, 2025 | wsj.comBlack Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant UpsideJune 10, 2025 | seekingalpha.comBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comTD Cowen Remains a Buy on Black Diamond Therapeutics (BDTX)May 15, 2025 | theglobeandmail.comSee More Headlines BDTX Stock Analysis - Frequently Asked Questions How have BDTX shares performed this year? Black Diamond Therapeutics' stock was trading at $2.14 at the start of the year. Since then, BDTX stock has increased by 12.1% and is now trading at $2.40. How were Black Diamond Therapeutics' earnings last quarter? Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) announced its earnings results on Thursday, August, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.06. When did Black Diamond Therapeutics IPO? Black Diamond Therapeutics (BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Black Diamond Therapeutics' major shareholders? Black Diamond Therapeutics' top institutional investors include Geode Capital Management LLC (0.87%), DLK Investment Management LLC (0.04%), Bailard Inc. (0.03%) and Y Intercept Hong Kong Ltd (0.03%). Insiders that own company stock include Ali Behbahani, Growth N V Biotech and David M Epstein. View institutional ownership trends. How do I buy shares of Black Diamond Therapeutics? Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Black Diamond Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR). Company Calendar Last Earnings3/06/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BDTX CIK1701541 WebN/A Phone617-252-0848FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Black Diamond Therapeutics$12.80 High Price Target$15.00 Low Price Target$11.00 Potential Upside/Downside+455.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.06 Trailing P/E Ratio38.42 Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.68 million Net MarginsN/A Pretax Margin7.27% Return on Equity4.70% Return on Assets3.47% Debt Debt-to-Equity RatioN/A Current Ratio9.24 Quick Ratio9.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.57Miscellaneous Outstanding Shares56,860,000Free Float53,468,000Market Cap$131.06 million OptionableOptionable Beta2.87 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BDTX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.